PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months earlier than conventional methods. This is the first robust clinical validation study of pan-cancer chemotherapy monitoring, published in the Journal of Liquid Biopsy. The study used a tissue-free, methylat. ...